Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending June 17, 2022.
Welcome to NeurologyLive®'s Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive®'s widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.
David S. Knopman, MD, writes on the journey of aducanumab (Aduhelm; Biogen) from development to the FDA—a tortured one. But, its path may serve to teach the Alzheimer disease field valuable lessons as it strives forward to develop disease-modifying therapies.
Mind Moments™, a podcast from NeurologyLive®, brings you exclusive interviews with experts in the treatment and management of sleep disorders as a recap of the 2022 SLEEP Annual Meeting.
The associate neurologist at Brigham and Women’s Hospital discussed the potential of a nasal anti-CD3 monoclonal antibody, foralumab, and its impact on biomarkers specific to patients with progressive multiple sclerosis.
The associate professor at the North Carolina Agricultural and Technical State University discussed a newfound initiative that helps encourage more professionals in multiple sclerosis and across the breadth of neurology.
Jessica Ailani, MD, and Arathi Nandyala, MD, write that although new treatments and innovations are a sign of growth in migraine care, it is important to realize that growth comes with a certain amount of pain. In clinical practice, choosing the right treatment option for patients in a time-limited visit is often a dilemma.